The Clinical Trials team is led by Dr Cath Mummery and runs a number of clinical trials. These treatment trials are vitally important to allow us to develop and test medicines that may slow the progression of diseases causing dementia, or even prevent the onset of symptoms.
Why we do clinical trials
The aim of a clinical trial is to test whether a particular drug has a beneficial effect. This involves investigating how a drug impacts dementia symptoms, but will also include monitoring its safety and/or assessing its effect on other indicators of a disease’s progression. Most studies are ‘randomised placebo controlled trials’. In these, in order to test the effect a drug may have, participants are assigned to one of two main groups: one of these groups will be given the active medication and the other will be administered a placebo that contains no active medication. Participants are assigned to either group at random, and neither you nor the study team will know which group you are assigned to during the trial. The drugs in our trials are administered orally (taking a pill), through infusion (via an intravenous (IV) drip) or by lumbar puncture injection (an injection into your lower back).
If you would like more information about taking part in our clinical trials, please email firstname.lastname@example.org, or call +44 (0) 20 3448 3105.
The DRC also actively supports Join Dementia Research which matches participants to appropriate research studies throughout the UK.
If you are interested in participating in our clinical trials or other research, please email our recruitment team at email@example.com, or call us on 020 3448 3105 during office hours to speak to a member of our team.